Global CD30 (TNFRSF8) Antibody Market Research Report 2024(Status and Outlook)
Report Overview:
CD30 (TNFRSF8) Antibody is an antibody specific for CD30 protein.
The Global CD30 (TNFRSF8) Antibody Market Size was estimated at USD 444.47 million in 2023 and is projected to reach USD 896.28 million by 2029, exhibiting a CAGR of 12.40% during the forecast period.
This report provides a deep insight into the global CD30 (TNFRSF8) Antibody market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global CD30 (TNFRSF8) Antibody Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the CD30 (TNFRSF8) Antibody market in any manner.
Global CD30 (TNFRSF8) Antibody Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sino Biological, Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co., Ltd.
Boster Biological Technology
MyBiosource, Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology, Inc.
Creative Diagnostics
OriGene Technologies, Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Market Segmentation (by Type)
Monoclonal Antibody
Polyclonal Antibody
Market Segmentation (by Application)
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CD30 (TNFRSF8) Antibody Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
CD30 (TNFRSF8) Antibody is an antibody specific for CD30 protein.
The Global CD30 (TNFRSF8) Antibody Market Size was estimated at USD 444.47 million in 2023 and is projected to reach USD 896.28 million by 2029, exhibiting a CAGR of 12.40% during the forecast period.
This report provides a deep insight into the global CD30 (TNFRSF8) Antibody market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global CD30 (TNFRSF8) Antibody Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the CD30 (TNFRSF8) Antibody market in any manner.
Global CD30 (TNFRSF8) Antibody Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sino Biological, Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co., Ltd.
Boster Biological Technology
MyBiosource, Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology, Inc.
Creative Diagnostics
OriGene Technologies, Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Market Segmentation (by Type)
Monoclonal Antibody
Polyclonal Antibody
Market Segmentation (by Application)
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the CD30 (TNFRSF8) Antibody Market
- Overview of the regional outlook of the CD30 (TNFRSF8) Antibody Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CD30 (TNFRSF8) Antibody Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of CD30 (TNFRSF8) Antibody
1.2 Key Market Segments
1.2.1 CD30 (TNFRSF8) Antibody Segment by Type
1.2.2 CD30 (TNFRSF8) Antibody Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CD30 (TNFRSF8) ANTIBODY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CD30 (TNFRSF8) ANTIBODY MARKET COMPETITIVE LANDSCAPE
3.1 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2019-2024)
3.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2019-2024)
3.3 CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global CD30 (TNFRSF8) Antibody Average Price by Manufacturers (2019-2024)
3.5 Manufacturers CD30 (TNFRSF8) Antibody Sales Sites, Area Served, Product Type
3.6 CD30 (TNFRSF8) Antibody Market Competitive Situation and Trends
3.6.1 CD30 (TNFRSF8) Antibody Market Concentration Rate
3.6.2 Global 5 and 10 Largest CD30 (TNFRSF8) Antibody Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CD30 (TNFRSF8) ANTIBODY INDUSTRY CHAIN ANALYSIS
4.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CD30 (TNFRSF8) ANTIBODY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
6.3 Global CD30 (TNFRSF8) Antibody Market Size Market Share by Type (2019-2024)
6.4 Global CD30 (TNFRSF8) Antibody Price by Type (2019-2024)
7 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CD30 (TNFRSF8) Antibody Market Sales by Application (2019-2024)
7.3 Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Application (2019-2024)
7.4 Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
8 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY REGION
8.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Region
8.2 North America
8.2.1 North America CD30 (TNFRSF8) Antibody Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe CD30 (TNFRSF8) Antibody Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America CD30 (TNFRSF8) Antibody Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Sino Biological, Inc.
9.1.1 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.1.2 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.1.4 Sino Biological, Inc. Business Overview
9.1.5 Sino Biological, Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
9.1.6 Sino Biological, Inc. Recent Developments
9.2 Bio-Techne
9.2.1 Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
9.2.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
9.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Product Market Performance
9.2.4 Bio-Techne Business Overview
9.2.5 Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
9.2.6 Bio-Techne Recent Developments
9.3 Thermo Fisher Scientific (China) Co., Ltd.
9.3.1 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Basic Information
9.3.2 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
9.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Market Performance
9.3.4 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody SWOT Analysis
9.3.5 Thermo Fisher Scientific (China) Co., Ltd. Business Overview
9.3.6 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
9.4 Boster Biological Technology
9.4.1 Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
9.4.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
9.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Market Performance
9.4.4 Boster Biological Technology Business Overview
9.4.5 Boster Biological Technology Recent Developments
9.5 MyBiosource, Inc.
9.5.1 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.5.2 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.5.4 MyBiosource, Inc. Business Overview
9.5.5 MyBiosource, Inc. Recent Developments
9.6 Abeomics Inc.
9.6.1 Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
9.6.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
9.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.6.4 Abeomics Inc. Business Overview
9.6.5 Abeomics Inc. Recent Developments
9.7 Abbexa
9.7.1 Abbexa CD30 (TNFRSF8) Antibody Basic Information
9.7.2 Abbexa CD30 (TNFRSF8) Antibody Product Overview
9.7.3 Abbexa CD30 (TNFRSF8) Antibody Product Market Performance
9.7.4 Abbexa Business Overview
9.7.5 Abbexa Recent Developments
9.8 Cell Signaling Technology, Inc.
9.8.1 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.8.2 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.8.4 Cell Signaling Technology, Inc. Business Overview
9.8.5 Cell Signaling Technology, Inc. Recent Developments
9.9 Creative Diagnostics
9.9.1 Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
9.9.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
9.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Market Performance
9.9.4 Creative Diagnostics Business Overview
9.9.5 Creative Diagnostics Recent Developments
9.10 OriGene Technologies, Inc.
9.10.1 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.10.2 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.10.4 OriGene Technologies, Inc. Business Overview
9.10.5 OriGene Technologies, Inc. Recent Developments
9.11 Merck
9.11.1 Merck CD30 (TNFRSF8) Antibody Basic Information
9.11.2 Merck CD30 (TNFRSF8) Antibody Product Overview
9.11.3 Merck CD30 (TNFRSF8) Antibody Product Market Performance
9.11.4 Merck Business Overview
9.11.5 Merck Recent Developments
9.12 Cayman Chemical
9.12.1 Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
9.12.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
9.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product Market Performance
9.12.4 Cayman Chemical Business Overview
9.12.5 Cayman Chemical Recent Developments
9.13 CUSABIO
9.13.1 CUSABIO CD30 (TNFRSF8) Antibody Basic Information
9.13.2 CUSABIO CD30 (TNFRSF8) Antibody Product Overview
9.13.3 CUSABIO CD30 (TNFRSF8) Antibody Product Market Performance
9.13.4 CUSABIO Business Overview
9.13.5 CUSABIO Recent Developments
9.14 Biotium
9.14.1 Biotium CD30 (TNFRSF8) Antibody Basic Information
9.14.2 Biotium CD30 (TNFRSF8) Antibody Product Overview
9.14.3 Biotium CD30 (TNFRSF8) Antibody Product Market Performance
9.14.4 Biotium Business Overview
9.14.5 Biotium Recent Developments
9.15 BioLegend
9.15.1 BioLegend CD30 (TNFRSF8) Antibody Basic Information
9.15.2 BioLegend CD30 (TNFRSF8) Antibody Product Overview
9.15.3 BioLegend CD30 (TNFRSF8) Antibody Product Market Performance
9.15.4 BioLegend Business Overview
9.15.5 BioLegend Recent Developments
9.16 Abcepta
9.16.1 Abcepta CD30 (TNFRSF8) Antibody Basic Information
9.16.2 Abcepta CD30 (TNFRSF8) Antibody Product Overview
9.16.3 Abcepta CD30 (TNFRSF8) Antibody Product Market Performance
9.16.4 Abcepta Business Overview
9.16.5 Abcepta Recent Developments
9.17 ProSci Incorporated
9.17.1 ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
9.17.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
9.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Market Performance
9.17.4 ProSci Incorporated Business Overview
9.17.5 ProSci Incorporated Recent Developments
10 CD30 (TNFRSF8) ANTIBODY MARKET FORECAST BY REGION
10.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast
10.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country
10.2.3 Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region
10.2.4 South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of CD30 (TNFRSF8) Antibody by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global CD30 (TNFRSF8) Antibody Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of CD30 (TNFRSF8) Antibody by Type (2025-2030)
11.1.2 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of CD30 (TNFRSF8) Antibody by Type (2025-2030)
11.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Application (2025-2030)
11.2.1 Global CD30 (TNFRSF8) Antibody Sales (Kilotons) Forecast by Application
11.2.2 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of CD30 (TNFRSF8) Antibody
1.2 Key Market Segments
1.2.1 CD30 (TNFRSF8) Antibody Segment by Type
1.2.2 CD30 (TNFRSF8) Antibody Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CD30 (TNFRSF8) ANTIBODY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CD30 (TNFRSF8) ANTIBODY MARKET COMPETITIVE LANDSCAPE
3.1 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2019-2024)
3.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2019-2024)
3.3 CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global CD30 (TNFRSF8) Antibody Average Price by Manufacturers (2019-2024)
3.5 Manufacturers CD30 (TNFRSF8) Antibody Sales Sites, Area Served, Product Type
3.6 CD30 (TNFRSF8) Antibody Market Competitive Situation and Trends
3.6.1 CD30 (TNFRSF8) Antibody Market Concentration Rate
3.6.2 Global 5 and 10 Largest CD30 (TNFRSF8) Antibody Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CD30 (TNFRSF8) ANTIBODY INDUSTRY CHAIN ANALYSIS
4.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CD30 (TNFRSF8) ANTIBODY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
6.3 Global CD30 (TNFRSF8) Antibody Market Size Market Share by Type (2019-2024)
6.4 Global CD30 (TNFRSF8) Antibody Price by Type (2019-2024)
7 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CD30 (TNFRSF8) Antibody Market Sales by Application (2019-2024)
7.3 Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Application (2019-2024)
7.4 Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
8 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY REGION
8.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Region
8.2 North America
8.2.1 North America CD30 (TNFRSF8) Antibody Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe CD30 (TNFRSF8) Antibody Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America CD30 (TNFRSF8) Antibody Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Sino Biological, Inc.
9.1.1 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.1.2 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.1.4 Sino Biological, Inc. Business Overview
9.1.5 Sino Biological, Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
9.1.6 Sino Biological, Inc. Recent Developments
9.2 Bio-Techne
9.2.1 Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
9.2.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
9.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Product Market Performance
9.2.4 Bio-Techne Business Overview
9.2.5 Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
9.2.6 Bio-Techne Recent Developments
9.3 Thermo Fisher Scientific (China) Co., Ltd.
9.3.1 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Basic Information
9.3.2 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
9.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Market Performance
9.3.4 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody SWOT Analysis
9.3.5 Thermo Fisher Scientific (China) Co., Ltd. Business Overview
9.3.6 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
9.4 Boster Biological Technology
9.4.1 Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
9.4.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
9.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Market Performance
9.4.4 Boster Biological Technology Business Overview
9.4.5 Boster Biological Technology Recent Developments
9.5 MyBiosource, Inc.
9.5.1 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.5.2 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.5.4 MyBiosource, Inc. Business Overview
9.5.5 MyBiosource, Inc. Recent Developments
9.6 Abeomics Inc.
9.6.1 Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
9.6.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
9.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.6.4 Abeomics Inc. Business Overview
9.6.5 Abeomics Inc. Recent Developments
9.7 Abbexa
9.7.1 Abbexa CD30 (TNFRSF8) Antibody Basic Information
9.7.2 Abbexa CD30 (TNFRSF8) Antibody Product Overview
9.7.3 Abbexa CD30 (TNFRSF8) Antibody Product Market Performance
9.7.4 Abbexa Business Overview
9.7.5 Abbexa Recent Developments
9.8 Cell Signaling Technology, Inc.
9.8.1 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.8.2 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.8.4 Cell Signaling Technology, Inc. Business Overview
9.8.5 Cell Signaling Technology, Inc. Recent Developments
9.9 Creative Diagnostics
9.9.1 Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
9.9.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
9.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Market Performance
9.9.4 Creative Diagnostics Business Overview
9.9.5 Creative Diagnostics Recent Developments
9.10 OriGene Technologies, Inc.
9.10.1 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Basic Information
9.10.2 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
9.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Market Performance
9.10.4 OriGene Technologies, Inc. Business Overview
9.10.5 OriGene Technologies, Inc. Recent Developments
9.11 Merck
9.11.1 Merck CD30 (TNFRSF8) Antibody Basic Information
9.11.2 Merck CD30 (TNFRSF8) Antibody Product Overview
9.11.3 Merck CD30 (TNFRSF8) Antibody Product Market Performance
9.11.4 Merck Business Overview
9.11.5 Merck Recent Developments
9.12 Cayman Chemical
9.12.1 Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
9.12.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
9.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product Market Performance
9.12.4 Cayman Chemical Business Overview
9.12.5 Cayman Chemical Recent Developments
9.13 CUSABIO
9.13.1 CUSABIO CD30 (TNFRSF8) Antibody Basic Information
9.13.2 CUSABIO CD30 (TNFRSF8) Antibody Product Overview
9.13.3 CUSABIO CD30 (TNFRSF8) Antibody Product Market Performance
9.13.4 CUSABIO Business Overview
9.13.5 CUSABIO Recent Developments
9.14 Biotium
9.14.1 Biotium CD30 (TNFRSF8) Antibody Basic Information
9.14.2 Biotium CD30 (TNFRSF8) Antibody Product Overview
9.14.3 Biotium CD30 (TNFRSF8) Antibody Product Market Performance
9.14.4 Biotium Business Overview
9.14.5 Biotium Recent Developments
9.15 BioLegend
9.15.1 BioLegend CD30 (TNFRSF8) Antibody Basic Information
9.15.2 BioLegend CD30 (TNFRSF8) Antibody Product Overview
9.15.3 BioLegend CD30 (TNFRSF8) Antibody Product Market Performance
9.15.4 BioLegend Business Overview
9.15.5 BioLegend Recent Developments
9.16 Abcepta
9.16.1 Abcepta CD30 (TNFRSF8) Antibody Basic Information
9.16.2 Abcepta CD30 (TNFRSF8) Antibody Product Overview
9.16.3 Abcepta CD30 (TNFRSF8) Antibody Product Market Performance
9.16.4 Abcepta Business Overview
9.16.5 Abcepta Recent Developments
9.17 ProSci Incorporated
9.17.1 ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
9.17.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
9.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Market Performance
9.17.4 ProSci Incorporated Business Overview
9.17.5 ProSci Incorporated Recent Developments
10 CD30 (TNFRSF8) ANTIBODY MARKET FORECAST BY REGION
10.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast
10.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country
10.2.3 Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region
10.2.4 South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of CD30 (TNFRSF8) Antibody by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global CD30 (TNFRSF8) Antibody Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of CD30 (TNFRSF8) Antibody by Type (2025-2030)
11.1.2 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of CD30 (TNFRSF8) Antibody by Type (2025-2030)
11.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Application (2025-2030)
11.2.1 Global CD30 (TNFRSF8) Antibody Sales (Kilotons) Forecast by Application
11.2.2 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. CD30 (TNFRSF8) Antibody Market Size Comparison by Region (M USD)
Table 5. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2019-2024)
Table 7. Global CD30 (TNFRSF8) Antibody Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD30 (TNFRSF8) Antibody as of 2022)
Table 10. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers CD30 (TNFRSF8) Antibody Sales Sites and Area Served
Table 12. Manufacturers CD30 (TNFRSF8) Antibody Product Type
Table 13. Global CD30 (TNFRSF8) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of CD30 (TNFRSF8) Antibody
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CD30 (TNFRSF8) Antibody Market Challenges
Table 22. Global CD30 (TNFRSF8) Antibody Sales by Type (Kilotons)
Table 23. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 24. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) by Type (2019-2024)
Table 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
Table 26. Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Type (2019-2024)
Table 27. Global CD30 (TNFRSF8) Antibody Market Size Share by Type (2019-2024)
Table 28. Global CD30 (TNFRSF8) Antibody Price (USD/Ton) by Type (2019-2024)
Table 29. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) by Application
Table 30. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 31. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (Kilotons)
Table 32. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Table 33. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (M USD)
Table 34. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Table 35. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Table 36. Global CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (Kilotons)
Table 37. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Table 38. North America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (Kilotons)
Table 41. South America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (Kilotons)
Table 43. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 44. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 45. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Sino Biological, Inc. Business Overview
Table 47. Sino Biological, Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
Table 48. Sino Biological, Inc. Recent Developments
Table 49. Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
Table 50. Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
Table 51. Bio-Techne CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Bio-Techne Business Overview
Table 53. Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
Table 54. Bio-Techne Recent Developments
Table 55. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Basic Information
Table 56. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
Table 57. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody SWOT Analysis
Table 59. Thermo Fisher Scientific (China) Co., Ltd. Business Overview
Table 60. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
Table 61. Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
Table 62. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
Table 63. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Boster Biological Technology Business Overview
Table 65. Boster Biological Technology Recent Developments
Table 66. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 67. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 68. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. MyBiosource, Inc. Business Overview
Table 70. MyBiosource, Inc. Recent Developments
Table 71. Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 72. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 73. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Abeomics Inc. Business Overview
Table 75. Abeomics Inc. Recent Developments
Table 76. Abbexa CD30 (TNFRSF8) Antibody Basic Information
Table 77. Abbexa CD30 (TNFRSF8) Antibody Product Overview
Table 78. Abbexa CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Abbexa Business Overview
Table 80. Abbexa Recent Developments
Table 81. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 82. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 83. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Cell Signaling Technology, Inc. Business Overview
Table 85. Cell Signaling Technology, Inc. Recent Developments
Table 86. Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
Table 87. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
Table 88. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Creative Diagnostics Business Overview
Table 90. Creative Diagnostics Recent Developments
Table 91. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 92. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 93. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. OriGene Technologies, Inc. Business Overview
Table 95. OriGene Technologies, Inc. Recent Developments
Table 96. Merck CD30 (TNFRSF8) Antibody Basic Information
Table 97. Merck CD30 (TNFRSF8) Antibody Product Overview
Table 98. Merck CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Merck Business Overview
Table 100. Merck Recent Developments
Table 101. Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
Table 102. Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
Table 103. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Cayman Chemical Business Overview
Table 105. Cayman Chemical Recent Developments
Table 106. CUSABIO CD30 (TNFRSF8) Antibody Basic Information
Table 107. CUSABIO CD30 (TNFRSF8) Antibody Product Overview
Table 108. CUSABIO CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. CUSABIO Business Overview
Table 110. CUSABIO Recent Developments
Table 111. Biotium CD30 (TNFRSF8) Antibody Basic Information
Table 112. Biotium CD30 (TNFRSF8) Antibody Product Overview
Table 113. Biotium CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Biotium Business Overview
Table 115. Biotium Recent Developments
Table 116. BioLegend CD30 (TNFRSF8) Antibody Basic Information
Table 117. BioLegend CD30 (TNFRSF8) Antibody Product Overview
Table 118. BioLegend CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. BioLegend Business Overview
Table 120. BioLegend Recent Developments
Table 121. Abcepta CD30 (TNFRSF8) Antibody Basic Information
Table 122. Abcepta CD30 (TNFRSF8) Antibody Product Overview
Table 123. Abcepta CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Abcepta Business Overview
Table 125. Abcepta Recent Developments
Table 126. ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
Table 127. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
Table 128. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. ProSci Incorporated Business Overview
Table 130. ProSci Incorporated Recent Developments
Table 131. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2030) & (Kilotons)
Table 132. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2030) & (M USD)
Table 133. North America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2030) & (Kilotons)
Table 134. North America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 135. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2030) & (Kilotons)
Table 136. Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 137. Asia Pacific CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2030) & (Kilotons)
Table 138. Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2030) & (M USD)
Table 139. South America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2030) & (Kilotons)
Table 140. South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 141. Middle East and Africa CD30 (TNFRSF8) Antibody Consumption Forecast by Country (2025-2030) & (Units)
Table 142. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 143. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2025-2030) & (Kilotons)
Table 144. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2030) & (M USD)
Table 145. Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2025-2030) & (USD/Ton)
Table 146. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) Forecast by Application (2025-2030)
Table 147. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. CD30 (TNFRSF8) Antibody Market Size Comparison by Region (M USD)
Table 5. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2019-2024)
Table 7. Global CD30 (TNFRSF8) Antibody Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD30 (TNFRSF8) Antibody as of 2022)
Table 10. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers CD30 (TNFRSF8) Antibody Sales Sites and Area Served
Table 12. Manufacturers CD30 (TNFRSF8) Antibody Product Type
Table 13. Global CD30 (TNFRSF8) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of CD30 (TNFRSF8) Antibody
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CD30 (TNFRSF8) Antibody Market Challenges
Table 22. Global CD30 (TNFRSF8) Antibody Sales by Type (Kilotons)
Table 23. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 24. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) by Type (2019-2024)
Table 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
Table 26. Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Type (2019-2024)
Table 27. Global CD30 (TNFRSF8) Antibody Market Size Share by Type (2019-2024)
Table 28. Global CD30 (TNFRSF8) Antibody Price (USD/Ton) by Type (2019-2024)
Table 29. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) by Application
Table 30. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 31. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (Kilotons)
Table 32. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Table 33. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (M USD)
Table 34. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Table 35. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Table 36. Global CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (Kilotons)
Table 37. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Table 38. North America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (Kilotons)
Table 41. South America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (Kilotons)
Table 43. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 44. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 45. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Sino Biological, Inc. Business Overview
Table 47. Sino Biological, Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
Table 48. Sino Biological, Inc. Recent Developments
Table 49. Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
Table 50. Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
Table 51. Bio-Techne CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Bio-Techne Business Overview
Table 53. Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
Table 54. Bio-Techne Recent Developments
Table 55. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Basic Information
Table 56. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Overview
Table 57. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody SWOT Analysis
Table 59. Thermo Fisher Scientific (China) Co., Ltd. Business Overview
Table 60. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
Table 61. Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
Table 62. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
Table 63. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Boster Biological Technology Business Overview
Table 65. Boster Biological Technology Recent Developments
Table 66. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 67. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 68. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. MyBiosource, Inc. Business Overview
Table 70. MyBiosource, Inc. Recent Developments
Table 71. Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 72. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 73. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Abeomics Inc. Business Overview
Table 75. Abeomics Inc. Recent Developments
Table 76. Abbexa CD30 (TNFRSF8) Antibody Basic Information
Table 77. Abbexa CD30 (TNFRSF8) Antibody Product Overview
Table 78. Abbexa CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Abbexa Business Overview
Table 80. Abbexa Recent Developments
Table 81. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 82. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 83. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Cell Signaling Technology, Inc. Business Overview
Table 85. Cell Signaling Technology, Inc. Recent Developments
Table 86. Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
Table 87. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
Table 88. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Creative Diagnostics Business Overview
Table 90. Creative Diagnostics Recent Developments
Table 91. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 92. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 93. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. OriGene Technologies, Inc. Business Overview
Table 95. OriGene Technologies, Inc. Recent Developments
Table 96. Merck CD30 (TNFRSF8) Antibody Basic Information
Table 97. Merck CD30 (TNFRSF8) Antibody Product Overview
Table 98. Merck CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Merck Business Overview
Table 100. Merck Recent Developments
Table 101. Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
Table 102. Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
Table 103. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Cayman Chemical Business Overview
Table 105. Cayman Chemical Recent Developments
Table 106. CUSABIO CD30 (TNFRSF8) Antibody Basic Information
Table 107. CUSABIO CD30 (TNFRSF8) Antibody Product Overview
Table 108. CUSABIO CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. CUSABIO Business Overview
Table 110. CUSABIO Recent Developments
Table 111. Biotium CD30 (TNFRSF8) Antibody Basic Information
Table 112. Biotium CD30 (TNFRSF8) Antibody Product Overview
Table 113. Biotium CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Biotium Business Overview
Table 115. Biotium Recent Developments
Table 116. BioLegend CD30 (TNFRSF8) Antibody Basic Information
Table 117. BioLegend CD30 (TNFRSF8) Antibody Product Overview
Table 118. BioLegend CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. BioLegend Business Overview
Table 120. BioLegend Recent Developments
Table 121. Abcepta CD30 (TNFRSF8) Antibody Basic Information
Table 122. Abcepta CD30 (TNFRSF8) Antibody Product Overview
Table 123. Abcepta CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Abcepta Business Overview
Table 125. Abcepta Recent Developments
Table 126. ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
Table 127. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
Table 128. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. ProSci Incorporated Business Overview
Table 130. ProSci Incorporated Recent Developments
Table 131. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2030) & (Kilotons)
Table 132. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2030) & (M USD)
Table 133. North America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2030) & (Kilotons)
Table 134. North America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 135. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2030) & (Kilotons)
Table 136. Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 137. Asia Pacific CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2030) & (Kilotons)
Table 138. Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2030) & (M USD)
Table 139. South America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2030) & (Kilotons)
Table 140. South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 141. Middle East and Africa CD30 (TNFRSF8) Antibody Consumption Forecast by Country (2025-2030) & (Units)
Table 142. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2030) & (M USD)
Table 143. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2025-2030) & (Kilotons)
Table 144. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2030) & (M USD)
Table 145. Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2025-2030) & (USD/Ton)
Table 146. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) Forecast by Application (2025-2030)
Table 147. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of CD30 (TNFRSF8) Antibody
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CD30 (TNFRSF8) Antibody Market Size (M USD), 2019-2030
Figure 5. Global CD30 (TNFRSF8) Antibody Market Size (M USD) (2019-2030)
Figure 6. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CD30 (TNFRSF8) Antibody Market Size by Country (M USD)
Figure 11. CD30 (TNFRSF8) Antibody Sales Share by Manufacturers in 2023
Figure 12. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers in 2023
Figure 13. CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by CD30 (TNFRSF8) Antibody Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global CD30 (TNFRSF8) Antibody Market Share by Type
Figure 18. Sales Market Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 19. Sales Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 20. Market Size Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 21. Market Size Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global CD30 (TNFRSF8) Antibody Market Share by Application
Figure 24. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Figure 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application in 2023
Figure 26. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Figure 27. Global CD30 (TNFRSF8) Antibody Market Share by Application in 2023
Figure 28. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Figure 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Figure 30. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 32. U.S. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada CD30 (TNFRSF8) Antibody Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico CD30 (TNFRSF8) Antibody Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 37. Germany CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific CD30 (TNFRSF8) Antibody Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 44. China CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America CD30 (TNFRSF8) Antibody Sales and Growth Rate (Kilotons)
Figure 50. South America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 51. Brazil CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 56. Saudi Arabia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global CD30 (TNFRSF8) Antibody Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Type (2025-2030)
Figure 65. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2025-2030)
Figure 66. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of CD30 (TNFRSF8) Antibody
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CD30 (TNFRSF8) Antibody Market Size (M USD), 2019-2030
Figure 5. Global CD30 (TNFRSF8) Antibody Market Size (M USD) (2019-2030)
Figure 6. Global CD30 (TNFRSF8) Antibody Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CD30 (TNFRSF8) Antibody Market Size by Country (M USD)
Figure 11. CD30 (TNFRSF8) Antibody Sales Share by Manufacturers in 2023
Figure 12. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers in 2023
Figure 13. CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by CD30 (TNFRSF8) Antibody Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global CD30 (TNFRSF8) Antibody Market Share by Type
Figure 18. Sales Market Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 19. Sales Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 20. Market Size Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 21. Market Size Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global CD30 (TNFRSF8) Antibody Market Share by Application
Figure 24. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Figure 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application in 2023
Figure 26. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Figure 27. Global CD30 (TNFRSF8) Antibody Market Share by Application in 2023
Figure 28. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Figure 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Figure 30. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 32. U.S. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada CD30 (TNFRSF8) Antibody Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico CD30 (TNFRSF8) Antibody Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 37. Germany CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific CD30 (TNFRSF8) Antibody Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 44. China CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America CD30 (TNFRSF8) Antibody Sales and Growth Rate (Kilotons)
Figure 50. South America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 51. Brazil CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 56. Saudi Arabia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global CD30 (TNFRSF8) Antibody Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Type (2025-2030)
Figure 65. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2025-2030)
Figure 66. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Application (2025-2030)
